abstract |
The present invention is a glycine transporter 1 (hereinafter referred to as GIyT-1) inhibitor and is therefore associated with schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), etc. Provided are compounds that are useful in the treatment of diseases treatable by inhibition of GIyT1, such as cognitive impairment. Also provided are pharmaceutical compositions containing the compounds and methods for preparing the compounds. |